Risk of hepatotoxicity in virologically suppressed HIV patients switching to nevirapine according to gender and CD4 count

被引：0
|
作者：
De Lazzari, E. [1 ]
Leon, A. [1 ]
Arnaiz, J. A. [1 ]
Martinez, E. [1 ]
Mallolas, J. M. [1 ]
Blanco, J. L. [1 ]
Laguno, M. [1 ]
Larrousse, M. [1 ]
Milinkovic, A. [1 ]
Lonca, M. [1 ]
Gatell, J. M. [1 ]
机构：
[1] Univ Barcelona, Barcelona, Spain
来源：
ANTIVIRAL THERAPY | 2006年 / 11卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：L8 / L8
页数：1
相关论文
共 50 条
  • [1] Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts
    De lazzari, E.
    Leon, A.
    Arnaiz, J. A.
    Martinez, E.
    Knobel, H.
    Negredo, E.
    Clotet, B.
    Montaner, J.
    Storfer, S.
    Asenjo, M. A.
    Mallolas, J.
    Miro, J. M.
    Gatell, J. M.
    HIV MEDICINE, 2008, 9 (04) : 221 - 226
  • [2] Nevirapine-associated hepatotoxicity in virologically suppressed patients role of gender and CD4+cell counts
    Mallolas, Josep
    AIDS REVIEWS, 2006, 8 (04) : 238 - 239
  • [3] Less frequent CD4 monitoring in virologically suppressed HIV
    McMahon, James
    Crowe, Suzanne M.
    LANCET HIV, 2017, 4 (06): : E233 - E234
  • [4] Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients
    Podzamczer, Daniel
    Olmo, Montserrat
    Sanz, Jose
    Boix, Vicente
    Negredo, Eugenia
    Knobel, Hernando
    Domingo, Pere
    Pineda, Juan A.
    Vilades, Consuelo
    Hernandez Quero, Jose
    Force, Lluis
    Gonzalez Lahoz, Juan
    Munoz, Pepa
    Llibre, Josep M.
    Marino, Ana
    Ortega, Enrique
    Dalmau, David
    Gatell, Josep M.
    Anton, Esperanza
    Sola, Julio
    Galindo, Maria J.
    Pedrol, Enric
    Sanz, Jesus
    Torre de Lima, Javier
    Flores, Juan
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 50 (04) : 390 - 396
  • [5] Gender Differences in Mortality and CD4 Count Response Among Virally Suppressed HIV-Positive Patients
    Maskew, Mhairi
    Brennan, Alana T.
    Westreich, Daniel
    McNamara, Lynne
    MacPhail, A. Patrick
    Fox, Matthew P.
    JOURNAL OF WOMENS HEALTH, 2013, 22 (02) : 113 - 120
  • [6] Risk of side effects associated with the use of nevirapine in treatment-naive patients, with respect to gender and CD4 cell count
    Knobel, H.
    Guelar, A.
    Montero, M.
    Carmona, A.
    Luque, S.
    Berenguer, N.
    Gonzalez, A.
    HIV MEDICINE, 2008, 9 (01) : 14 - 18
  • [7] Is necessary monitoring CD4 lymphocytes in HIV patients virologically stables?
    Llopis, Marina
    Cioaia, Simona
    Poquet, Inmaculada
    Tornero, Carlos
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2015, 33 (07): : 504 - 504
  • [8] Nadir CD4 T Cell Count as Predictor and High CD4 T Cell Intrinsic Apoptosis as Final Mechanism of Poor CD4 T Cell Recovery in Virologically Suppressed HIV-Infected Patients: Clinical Implications
    Negredo, Eugenia
    Massanella, Marta
    Puig, Jordi
    Perez-Alvarez, Nuria
    Miguel Gallego-Escuredo, Jose
    Villarroya, Joan
    Villarroya, Francesc
    Molto, Jose
    Ramon Santos, Jose
    Clotet, Bonaventura
    Blanco, Julia
    CLINICAL INFECTIOUS DISEASES, 2010, 50 (09) : 1300 - 1308
  • [9] Routine CD4 cell count monitoring seldom contributes to clinical decision-making on antiretroviral therapy in virologically suppressed HIV-infected patients
    Chow, E. P. F.
    Read, T. R. H.
    Chen, M. Y.
    Fehler, G.
    Bradshaw, C. S.
    Fairley, C. K.
    HIV MEDICINE, 2015, 16 (03) : 196 - 200
  • [10] Is It Safe to Discontinue Primary Pneumocystis jiroveci Pneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count <200 Cells/μL?
    Furrer, Hansjakob
    CLINICAL INFECTIOUS DISEASES, 2010, 51 (05) : 611 - 619
12345